-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $169

Benzinga·01/08/2026 17:22:12
Listen to the news
Truist Securities analyst Danielle Brill maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and lowers the price target from $172 to $169.